Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Iron chelation therapy in myelodysplastic syndromes.

    ... including efficacy, safety, and economic considerations for transfusion-dependent patients with MDS, is provided. SUMMARY: ... treatment. Supportive care measures such as red blood cell transfusions and erythroid colony stimulating factors are ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

    ... leukaemia (AML). Most MDS patients eventually require transfusion of red blood cells for anaemia, placing them at risk of transfusional iron ... patients may have improvement in cell counts and decreased transfusion requirements. While guidelines for MDS generally recommend ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous ... Risk-adapted therapy: Therapy is selected based on risk, transfusion needs, percent of bone marrow blasts and more recently cytogenetic ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous ... Risk-adapted therapy: Therapy is selected based on risk, transfusion needs, percent of bone marrow blasts, and, more recently, ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous ... RISK-ADAPTED THERAPY: Therapy is selected based on risk, transfusion needs, percent of bone marrow blasts and more recently cytogenetic ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Comparison of Rabbit Antithymocyte Globulin (R-ATG) and Jurkat Cell-Reactive Anti-T Lymphocyte Globulin (ATG-F) as a First-line Treatment for Children with Aplastic Anemia

    ... AA (SAA), 10 cases of very severe AA (VSAA) and 11 cases of transfusion-dependent non-severe AA (NSAA). While receiving immunosuppressive ... and/or infection control. Absolute counts of peripheral blood lymphocyte (ALC) in various time points were dynamically measured after ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Cotransplantation of allogeneic mesenchymal and hematopoietic stem cells in children with aplastic anemia

    ... factor-mobilized bone marrow and peripheral blood from HLA antigen-haploidentical donors (3 cases) or peripheral ... no chronic GvHD was documented. All patients were alive and transfusion independent at a median follow-up of 15 months (range: 6-29 ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Hematopoietic stem cell transplantation with umbilical cord multipotent stromal cell infusion for the treatment of aplastic anemia-a single-center experience.

    ... The purpose of this study was to observe the outcome of co-transfusion of umbilical cord multipotent stromal cells (UC-MSC) and allogeneic ... factor-primed bone marrow and peripheral blood grafts; the other patients received granulocyte colony-stimulating ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Clinical and genetic predictors of prognosis in myelodysplastic syndromes

    ... Most models include the presence or severity of peripheral blood cytopenias, the proportion of bone marrow blasts , and ... factors including age, performance status, co-morbidities, transfusion dependence, and molecular biomarkers can further refine the ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Molecular pathogenesis of myelodysplastic syndromes

    ... , hypercellular bone marrow , dysplasia of blood cells and cytopenias. Most patients are diagnosed in their late 60s to ... decitabine , and 5-azacytidine, are targeted to improve transfusion requirements and quality of life. Moreover, 5-azacytidine has also ...

    Research Article last updated 07/20/2018 - 5:15pm.